Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
NCT01730092
Recruiting
Background: - High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments. To further identify treatment targets, they will compare healthy volunteers to patients with PAH. Objectives: - To study the natur... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pulmonary Disease, Pulmonary Hypertension
Register for Updates
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT04802759
Recruiting
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor-positive (ER+), HER2-negative breast cancer who... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: City of Hope, Duarte, California +27 locations
Conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Register for Updates
Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers
NCT05652478
Recruiting
Background: People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understand how INSTIs cause weight changes. Objective: To see how a common INSTI, dolutegravir (DTG), affects how the body uses energy. DTG will be compared with a non-INSTI drug, tenofovir alafenamide (TAF... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metabolic Effects, Weight Gain, Integrase Strand Transfer Inhibitors, Healthy Volunteer
Register for Updates
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
NCT06066138
Recruiting
Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. One of these drugs (atezolizumab) is approved to treat certain cancers. Researchers want to find out if lower doses of this drug might provide the same benefit with fewer adverse effects. Objective: To test different doses and timing of atezolizumab for people with can... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced Small Cell Lung Cancer, Metastatic Small Cell Lung Cancer, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Melanoma, Metastatic Melanoma
Register for Updates
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806
Recruiting
This phase II trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +174 locations
Conditions: Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Register for Updates
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-Obstructive Disease
NCT06603246
Recruiting
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in patients with muco-obstructive disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Accel Research Site - Achieve - Birmingham - ERN - PPDS, Vestavia Hills, Alabama +1 locations
Conditions: Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
Register for Updates
Pathological Basis of MRI Signal Changes in Multiple Sclerosis
NCT02659956
Recruiting
Background: Multiple sclerosis (MS) is a disease that damages the central nervous system (brain and spinal cord). This leads to increased physical disability over time. The disease is lifelong once it begins. Researchers want to learn more about MS s stages and follow them until a person s death. Objective: To understand how the physical and clinical signs of MS relate to its changes over time. Eligibility: Adults age 18 or older with MS or a disease of the brain and spinal cord that may ac... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Register for Updates
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
NCT04865887
Recruiting
This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia +3 locations
Conditions: Cervical Cancer, Metastatic Cervical Cancer
Register for Updates
Observational Study of Advanced Data Analytics in Genetic Conditions
NCT05657405
Recruiting
Background: The genes a person is born with can sometimes cause serious diseases. Genetic diseases are rare, but they can have a big impact on the people they affect. Researchers have already made great strides in understanding how some genes cause disease. But they would like to have even better tools to analyze and understand genetic data. To create these new tools, they need to gather health and genetic data from a lot of people. Objective: This natural history study will gather medical in... Read More
Gender:
ALL
Ages:
Between 1 day and 120 years
Trial Updated:
05/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Genetic Conditions
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/08/2025
Locations: Alabama Neurology Associates- Site Number : 8400115, Birmingham, Alabama +327 locations
Conditions: Multiple Sclerosis
Register for Updates
A Study of Sacituzumab Govitecan in People With Mesothelioma
NCT06477419
Recruiting
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Pleura
Register for Updates
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
NCT06615050
Recruiting
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia +3 locations
Conditions: Graft-versus-host Disease (GVHD)
Register for Updates